{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncologic+Disorders&page=8", "query": { "condition": "Oncologic Disorders", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 752, "total_pages": 76, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncologic+Disorders&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oncologic+Disorders&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T08:32:20.192Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02538627", "title": "Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "MM-151", "type": "DRUG" }, { "name": "MM-121", "type": "DRUG" }, { "name": "MM-141", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-08", "completion_date": "2016-10-05", "has_results": false, "last_update_posted_date": "2017-09-05", "last_synced_at": "2026-10-22T08:32:20.192Z", "location_count": 5, "location_summary": "Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02538627" }, { "nct_id": "NCT00274469", "title": "A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "fulvestrant", "type": "DRUG" }, { "name": "anastrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "45 Years to 100 Years · Female only" }, "enrollment_count": 205, "start_date": "2006-02-06", "completion_date": "2017-01-13", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-10-22T08:32:20.192Z", "location_count": 5, "location_summary": "Frederick, Maryland • St Louis, Missouri • Teaneck, New Jersey + 2 more", "locations": [ { "city": "Frederick", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Teaneck", "state": "New Jersey" }, { "city": "Austin", "state": "Texas" }, { "city": "Duncanville", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00274469" }, { "nct_id": "NCT06844669", "title": "HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "HER2+ Breast Cancer" ], "interventions": [ { "name": "Carvedilol", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2025-04-16", "completion_date": "2026-05-07", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-22T08:32:20.192Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06844669" }, { "nct_id": "NCT01943851", "title": "A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK525762", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2014-05-14", "completion_date": "2020-04-30", "has_results": true, "last_update_posted_date": "2024-10-01", "last_synced_at": "2026-10-22T08:32:20.192Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Aurora, Colorado • New York, New York + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01943851" }, { "nct_id": "NCT03904069", "title": "Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "AMG 553", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 0, "start_date": "2023-03-13", "completion_date": "2030-08-07", "has_results": false, "last_update_posted_date": "2023-06-12", "last_synced_at": "2026-10-22T08:32:20.192Z", "location_count": 3, "location_summary": "Duarte, California • Palo Alto, California • Houston, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03904069" }, { "nct_id": "NCT00216086", "title": "Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "EUS", "type": "PROCEDURE" }, { "name": "Neoadjuvant Chemotherapy", "type": "DRUG" }, { "name": "Preoperative Radiation", "type": "PROCEDURE" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Adjuvant Chemotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Gabi Chiorean, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2005-05", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2016-06-06", "last_synced_at": "2026-10-22T08:32:20.192Z", "location_count": 9, "location_summary": "Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more", "locations": [ { "city": "Elkhart", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00216086" }, { "nct_id": "NCT05987332", "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "IDE196", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2023-10-31", "completion_date": "2028-01-15", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-22T08:32:20.192Z", "location_count": 31, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05987332" }, { "nct_id": "NCT07861347", "title": "Emulation of the KEYNOTE177 Trial Using Specialty Oncology Electronic Health Records Databases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Colorectal Cancer (mCRC)" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "5-fluorouracil-based chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1030, "start_date": "2026-08-13", "completion_date": "2026-11-13", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-22T08:32:20.192Z", "location_count": 1, "location_summary": "Somerville, Massachusetts", "locations": [ { "city": "Somerville", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07861347" }, { "nct_id": "NCT01748149", "title": "Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas" ], "interventions": [ { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 40, "start_date": "2014-04-29", "completion_date": "2025-07-31", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-10-22T08:32:20.192Z", "location_count": 20, "location_summary": "Los Angeles, California • Oakland, California • San Diego, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01748149" }, { "nct_id": "NCT01186458", "title": "Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Velcade", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoosier Cancer Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2010-10", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2016-10-24", "last_synced_at": "2026-10-22T08:32:20.192Z", "location_count": 11, "location_summary": "Bloomington, Indiana • Fort Wayne, Indiana • Indianapolis, Indiana + 6 more", "locations": [ { "city": "Bloomington", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186458" } ] }